Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

Central Arkansas Veterans Healthcare System and University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Blood (Impact Factor: 9.78). 09/2002; 100(4):1168-71. DOI: 10.1182/blood-2002-01-0335
Source: PubMed

ABSTRACT Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT). Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT. We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one. DT-PACE (dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide) was offered to patients with preceding standard dose therapy, but no prior autotransplantation, while DCEP-T (dexamethasone/cyclophosphamide/etoposide/cisplatin/thalidomide) was administered for relapse after transplantation. If there were signs or symptoms suggestive of DVT, patients received additional investigations, including Doppler ultrasonography, followed by venography if indicated. Only patients on DT-PACE but not DCEP-T experienced an increased incidence of DVT. A statistical association between the incidence of DVT and combination chemotherapy including doxorubicin (P =.02) was observed; this association was confirmed on multivariate analysis. MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT.

  • New England Journal of Medicine 10/2004; 351(18):1860-73. DOI:10.1056/NEJMra041875 · 54.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: El conocimiento de los factores pronósticos permite optimizar las estrategias terapéuticas del mieloma múltiple. El tratamiento se basa en la quimioterapia (en particular melfalán y corticoterapia) y en el trasplante, fundamentalmente el autotrasplante (trasplante autólogo) de células madre o primordiales periféricas. Los bifosfonatos son útiles para reducir las complicaciones óseas y la talidomida se emplea como tratamiento de segunda elección. Los recientes progresos alcanzados en materia de comprensión de la fisiopatología del mieloma permiten augurar el desarrollo de terapéuticas innovadoras.
    01/2003; 36(4):1–8. DOI:10.1016/S1286-935X(03)72293-X
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prompt diagnosis and treatment of pulmonary embolism (PE) can help reduce its associated morbidity and mortality. Computed tomography chest angiography (CTA) scanning is the most widely used diagnostic modality. In noncancer patients, only 10% of such studies are positive for PE. Clinical variables, individual or in combination, that can predict test positivity are highly needed. All CTAs requested to confirm or exclude a diagnosis of PE in a single comprehensive cancer center were reviewed. In addition to the Wells score, other clinical variables known to increase the risk of PE were analyzed. A total of 778 adult cancer patients were treated at King Hussein Cancer Center (Amman, Jordan) and were included in this study; the majority of patients (64.2%) had stage 4 disease. Overall, 129 (16.6%) patients had positive scans for PE, while alternative diagnoses were made in 308 (39.6%) patients. Cancer stage and anticancer treatment had no impact on positive PE rates. However, Wells criteria classified patients into three risk groups with PE rates of 10.2%, 16.1%, and 62.5% among the patients with low, moderate, and high risk, respectively (P < 0.0001). Duration of cancer diagnosis (<12 months versus >12 months) had a significant impact on positive PE studies (22.0% versus 12.4%, respectively, P = 0.007). The rate of positive PE studies in cancer patients is higher than previously reported in noncancer patients. Positivity for PE was higher during the first 12 months of cancer diagnosis and in those with high probability score according to the Wells criteria. Factors like primary tumor stage and anticancer therapy had no significant impact on PE-positive studies.
    Patient Preference and Adherence 01/2013; 7:1111-6. DOI:10.2147/PPA.S46372 · 1.49 Impact Factor

Full-text (2 Sources)

Available from
May 21, 2014